256383-44-5

Basic information

• Product Name: 4-N-HEPTYLBENZENE BORONIC ACID
• Synonyms: 4-N-HEPTYLPHENYLBORONIC ACID;4-N-HEPTYLBENZENE BORONIC ACID;AKOS BRN-0158;4-(Hept-1-yl)benzeneboronic acid;(4-Heptylphenyl)boronic acid
• CAS NO: 256383-44-5
• Molecular Formula: C₁₃H₂₁BO₂
• Molecular Weight: 220.12
• Mol File: 256383-44-5.mol
• Article Data: 3

Chemical Properties

• Melting Point: 50-70 °C(Solv: pentane (109-66-0))
• Boiling Point: 357 °C at 760 mmHg
• Flash Point: 169.7 °C
• Appearance: /
• Density: 0.99 cm³
• Vapor Pressure: 1.03E-05mmHg at 25°C
• Refractive Index: 1.504
• Storage Temp.: 2-8°C
• PKA: 8.72±0.16(Predicted)
• CAS DataBase Reference: 4-N-HEPTYLBENZENE BORONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-N-HEPTYLBENZENE BORONIC ACID(256383-44-5)
• EPA Substance Registry System: 4-N-HEPTYLBENZENE BORONIC ACID(256383-44-5)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 256383-44-5(Hazardous Substances Data)

Usage

Uses

4-N-Heptylphenylboronic acid is an inhibitor of endothelial lipase and lipoprotein lipase.

InChI:InChI=1/C13H21BO2/c1-2-3-4-5-6-7-12-8-10-13(11-9-12)14(15)16/h8-11,15-16H,2-7H2,1H3

Upstream product

• 192934-88-6 7-(4-nitrophenyl)heptane 
• 131894-91-2 1-(n-heptyl)-4-iodobenzene 
• 37529-27-4 4-heptylaniline 
• 17763-80-3 para-nitrophenyl triflate 
• 28741-07-3 heptyl boronic acid 
• 1359844-04-4 4-heptylphenylboronic acid pinacol ester 
• 76287-49-5 1-bromo-4-heptylbenzene 

Downstream Products

• 256383-47-8 1-(4-heptylphenyl)-2,6,1-dioxaborinane 
• 331834-18-5 5-(4-heptyl-phenyl)-benzo[b]thiophene 
• 1205548-87-3 5-(p-C₇H₁₅Ph)-7-azaindole 

Relevant articles and documents

Design and synthesis of boronic acid inhibitors of endothelial lipase

Endothelial lipase (EL) and lipoprotein lipase (LPL) are homologous lipases that act on plasma lipoproteins. EL is predominantly a phospholipase and appears to be a key regulator of plasma HDL-C. LPL is mainly a triglyceride lipase regulating (V)LDL levels. The existing biological data indicate that inhibitors selective for EL over LPL should have anti-atherogenic activity, mainly through increasing plasma HDL-C levels. We report here the synthesis of alkyl, aryl, or acyl-substituted phenylboronic acids that inhibit EL. Many of the inhibitors evaluated proved to be nearly equally potent against both EL and LPL, but several exhibited moderate to good selectivity for EL.

Highly efficient syntheses of 3-aryl-2-cycloalken-1-ones and an evaluation of their liquid crystalline properties

Cycloalkenones are shown to be mesogens and can be synthesised in near quantitative yields by a convergent palladium(0)-catalysed cross-coupling strategy; a 2-methyl group induces a change of phase from smectic to nematic.